Acarbose monotherapy and weight loss in Eastern and Western populations with hyperglycaemia: An ethnicity-specific meta-analysis

International Journal of Clinical Practice

Volumn 68, Issue 11, 2014, Pages 1318-1332

  Li, Y ^a   Tong, Y ^a   Zhang, Y ^a   Huang, L ^a   Wu, T ^a   Tong, Nanwei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; METFORMIN; NATEGLINIDE; PLACEBO; ANTIDIABETIC AGENT;

BODY MASS; BODY WEIGHT; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; ETHNICITY; HUMAN; HYPERGLYCEMIA; META ANALYSIS; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION; ASIAN CONTINENTAL ANCESTRY GROUP; CAUCASIAN; DIABETES MELLITUS, TYPE 2; ETHNOLOGY; FEMALE; GENETICS; MALE;

ACARBOSE; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; WEIGHT LOSS;

EID: 84916210163     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12467     Document Type: Review

References (56)

1. Anderson JW, Kendall CW, Jenkins DJ,. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003; 22: 331-9.
2. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001; 161: 1581-6.
3. Lean ME, Powrie JK, Anderson AS, Garthwaite PH,. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990; 7: 228-33.
4. Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Am J Clin Nutr 2004; 80: 257-63.
5. Clissold SP, Edwards C,. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1988; 35: 214-43.
6. Zhu Q, Tong Y, Wu T, et al. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an eastern or western diet: a systematic meta-analysis. Clin Ther 2013; 35: 880-99.
7. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7.
8. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-6.
9. Meneilly GS, Ryan EA, Radziuk J, et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000; 23: 1162-7.
10. Coniff RF, Shapiro JA, Seaton TB,. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 1994; 154: 2442-8.
11. Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732-7.
12. Chan JC, Chan KW, Ho LL, et al. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. Diabetes Care 1998; 21: 1058-61.
13. Pan CY, Gao Y, Chen JW, et al. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance. Diabetes Res Clin Pract 2003; 61: 183-90.
14. Zheng MY, Yang JH, Shan CY, et al. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol 2013; 12: 73.
15. Kataoka M, Venn BJ, Williams SM, et al. Glycaemic responses to glucose and rice in people of Chinese and European ethnicity. Diabet Med 2013; 30: e101-7.
16. Higgins JPT, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org (accessed April 2013).
17. WHO. Diabetes mellitus: Report of a WHO Study Group. World Health Organ Tech Rep Ser 1985; 727: 1-113.
18. WHO (1999) Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization, 1999 (WHO/NCD/NCS/99.2).
19. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-97.
20. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26 (Suppl. 1): S5-20.
21. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-57.
22. Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 18: CD003639.
23. Sedgwick P,. Meta-analyses: heterogeneity and subgroup analysis. BMJ 2013; 346: f4040.
24. Cheng Y, Xiong QX, Liu Q, et al. Comparison of clinical efficacy of nateglinide and acarbose in type 2 diabetes mellitus patients. Chin J Mod Drug Appl 2010; 4: 166-7.
25. Hotta N, Kakuta H, Sano T, et al. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabet Med 1993; 10: 134-8.
26. Hou WK, Zhang BZ,. The effect of acarbose on NIDDM patients: double-blind randomized controlled trial. Chin J Diabetes 1996; 4: 56-9.
27. Hu XM,. Clinical study of metformin and acarbose therapy in impaired glucose tolerance. Inter Natl Med Health Guidance News 2008; 14: 63-5.
28. Li L, Yang RL,. Protection of acarbose on vascular endothelial function in patients with impaired glucose tolerance. Chin J Postgrad Med 2011; 34: 37-9.
29. Pan CY, Gao Y, Li GW, et al. A comparison of efficacy and tolerance of nateglinide and acarbose monotherapy in type 2 diabetes mellitus. Chin J Intern Med 2009; 48: 304-7.
30. Su RT, Han RJ,. Effect of acarbose intervention on cases with impaired glucose tolerance. Chin J Postgrad Med 2006; 29: 14-6.
31. Wu GT, Han YQ, Yu YC, et al. Influence of acarbose on insulin resistant of patients with type 2 diabetes mellitus. Chin J New Drugs Clin Rem 2003; 22: 535-8.
32. Xu MT, Xiao MH, He L, et al. The metabolic effect of acarbose on impaired glucose tolerance patients. Guangdong Med J 2003; 24: 147-8.
33. Yang WY,. MARCH trial: comparison of metformin and acarbose for the new-onset type 2 diabetes in China. The 11th Annual Meeting of Chinese Society of Endocrinology. Guangzhou, Guangdong Province, China, 2012.
34. Zheng GF, Wang JP, Zhang H, et al. Clinical observation on glucobay treatment for NIDDM. Chin J Endocrinol Metab 1995; 11: 163-4.
35. Braun D, Schonherr U, Mitzkat HJ,. Efficacy of acarbose monotherapy in patients with type 2 diabetes: a double-blind study conducted in general practice. Endocrinology and Metabolism 1996; 3: 275-80.
36. Buchanan DR, Collier A, Rodrigues E, et al. Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes. Eur J Clin Pharmacol 1988; 34: 51-3.
37. Calle-Pascual A, Garcia-Honduvilla J, Martin-Alvarez PJ, et al. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo. Diabetes Metab 1996; 22: 201-2.
38. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-35.
39. Chiasson JL, Josse RG, Leiter LA, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19: 1190-3.
40. Coniff RF, Shapiro JA, Seaton TB, Bray GA,. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: 443-51.
41. Coniff RF, Shapiro JA, Robbins D, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes Care 1995; 18: 817-24.
42. Delgado H, Lehmann T, Bobbioni-Harsch E, et al. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 2002; 28: 195-200.
43. Derosa G, Maffioli P, Ferrari I, et al. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. Eur J Pharmacol 2011; 651: 240-50.
44. Fischer S, Hanefeld M, Spengler M, et al. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol 1998; 35: 34-40.
45. Haffner SM, Hanefeld M, Fischer S, et al. Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM. Diabetes Care 1997; 20: 1430-4.
46. Hoffmann J, Spengler M,. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994; 17: 561-6.
47. Hoffmann J, Spengler M,. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 1997; 103: 483-90.
48. Holman RR, Cull CA, Turner RC,. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999; 22: 960-4.
49. Holmes D, Raccah D, Escobar-Jimenez F, Standl E,. Targeting postprandial hyperglycemia to achieve glycemic control in patients with type 2 diabetes: a comparison of nateglinide and acarbose. Presented at the 37th European Association for the Study of Diabetes Congress, Glasgow, Scotland, 2001.
50. Kovacevic I, Profozic V, Skrabalo Z, et al. Multicentric clinical trial to assess efficacy and tolerability of acarbose (BAY G 5421) in comparison to glibenclamide and placebo. Diabetologia Croatica 1997; 26: 83-9.
51. Santeusanio F, Ventura MM, Contadini S, et al. Efficacy and safety of two different dosages of acarbose in non-insulin dependent diabetic patients treated by diet alone. Diabetes, Nutr Metabol Clin Exp 1993; 6: 147-54.
52. Seifarth C, Bergmann J, Holst JJ, et al. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients. Diabet Med 1998; 15: 485-91.
53. Hucking K, Kostic Z, Pox C, et al. Alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients. Diabet Med 2005; 22: 470-6.
54. Wolever TM, Chiasson JL, Josse RG, et al. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int J Obes Relat Metab Disord 1997; 21: 756-63.
55. Lindstrom J, Tuomilehto J, Spengler M,. Acarbose treatment does not change the habitual diet of patients with Type 2 diabetes mellitus. The Finnish Acargbos Study Group. Diabet Med 2000; 17: 20-5.
56. Santos JL, Saus E, Smalley SV, et al. Copy number polymorphism of the salivary amylase gene: implications in human nutrition research. J Nutrigenet Nutrigenomics 2012; 5: 117-31.